Diagnostic efficacy of MnDPDP in MR imaging of the liver: A phase III multicentre study
1997 (English)In: Acta Radiologica, ISSN 0284-1851, E-ISSN 1600-0455, Vol. 38, no 4 Pt 2, 643-649 p.Article in journal (Refereed) Published
To assess the diagnostic efficacy, safety and tolerability of mangafodipir trisodium (MnDPDP, Teslascan) in MR imaging of the liver.
MATERIAL AND METHODS:
Eighty-two patients from 4 centres underwent MR imaging with pre-contrast sequences including T1-weighted SE and GRE, and T2-weighted turbo SE sequences. MnDPDP at a dose of 5 mumol/kg b.w. was administered by slow i.v. infusion, and 20-60 min after infusion the T1-weighted SE and GRE sequences were repeated. Diagnostic efficacy was evaluated by counting the number of lesions and by evaluating whether more information for lesion characterisation was available in post-contrast images. Safety and tolerability were assessed by recording adverse events and infusion-related discomfort.
Significantly more lesions were found in MnDPDP-enhanced T1-weighted SE and GRE images than in unenhanced images of the same sequences. More lesions were also found in these images compared with T2-weighted images at a level of marginal significance. More information was obtained from MnDPDP-enhanced images in 40 cases. Mild to moderate adverse events were experienced by 17% of the patients.
MnDPDP-enhanced images can improve lesion detection in the liver and are helpful for lesion characterisation. To obtain optimal diagnostic information of liver lesions T2-weighted images are also valuable. MnDPDP is a safe contrast agent for MR imaging of liver lesions.
Place, publisher, year, edition, pages
1997. Vol. 38, no 4 Pt 2, 643-649 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-152976PubMedID: 9245958OAI: oai:DiVA.org:uu-152976DiVA: diva2:414788